Holloway R - Search Results

1

Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.

Noyes K, Liu H, Li Y, Holloway R, Dick AW. Noyes K, et al. Among authors: holloway r. Mov Disord. 2006 Mar;21(3):362-72. doi: 10.1002/mds.20727. Mov Disord. 2006. PMID: 16211621

2

Accuracy of Medicare claims data in identifying Parkinsonism cases: comparison with the Medicare current beneficiary survey.

Noyes K, Liu H, Holloway R, Dick AW. Noyes K, et al. Among authors: holloway r. Mov Disord. 2007 Mar 15;22(4):509-14. doi: 10.1002/mds.21299. Mov Disord. 2007. PMID: 17230477

3

Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.

Noyes K, Dick AW, Holloway RG; Parkinson Study Group. Noyes K, et al. Med Decis Making. 2004 Sep-Oct;24(5):472-85. doi: 10.1177/0272989X04268960. Med Decis Making. 2004. PMID: 15358996 Clinical Trial.

4

Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.

Noyes K, Dick AW, Holloway RG; Parkinson Study Group. Noyes K, et al. Pharmacoeconomics. 2005;23(12):1257-70. doi: 10.2165/00019053-200523120-00009. Pharmacoeconomics. 2005. PMID: 16336019 Clinical Trial.

5

What is the risk of developing parkinsonism following neuroleptic use?

Noyes K, Liu H, Holloway RG. Noyes K, et al. Neurology. 2006 Mar 28;66(6):941-3. doi: 10.1212/01.wnl.0000203348.13337.89. Neurology. 2006. PMID: 16567720

6

Evidence from cost-effectiveness research.

Noyes K, Holloway RG. Noyes K, et al. NeuroRx. 2004 Jul;1(3):348-55. doi: 10.1602/neurorx.1.3.348. NeuroRx. 2004. PMID: 15717037 Free PMC article. Review.

7

Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life.

Noyes K, Dick AW, Holloway RG; Parkinson Study Group. Noyes K, et al. Value Health. 2006 Jan-Feb;9(1):28-38. doi: 10.1111/j.1524-4733.2006.00078.x. Value Health. 2006. PMID: 16441522 Free article. Clinical Trial.

8

The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.

Noyes K, Dick AW, Holloway RG. Noyes K, et al. Med Decis Making. 2007 May-Jun;27(3):327-34. doi: 10.1177/0272989X07301822. Epub 2007 May 14. Med Decis Making. 2007. PMID: 17502449 Clinical Trial.

9

Clinical trial end points: on the road to nowhere?

Holloway RG, Dick AW. Holloway RG, et al. Neurology. 2002 Mar 12;58(5):679-86. doi: 10.1212/wnl.58.5.679. Neurology. 2002. PMID: 11889228

10

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.

Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, Holloway RG, Dick AW. Noyes K, et al. Among authors: holloway rg. Neurology. 2011 Jul 26;77(4):355-63. doi: 10.1212/WNL.0b013e3182270402. Epub 2011 Jul 20. Neurology. 2011. PMID: 21775734 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

831 results

Search Page

Filters